What Neurotensin is
Neurotensin is an endogenous neuropeptide involved in gut-brain signaling, pain, temperature, and dopamine-related pathways.
Neurotensin is grouped under Endogenous / Biology on PeptideFactCheck because it matters as a systems-biology peptide rather than a trendy product name.
The useful starting point is to separate the molecule itself from the internet story around it. It matters as a systems-biology peptide rather than a trendy product name.
Why people keep looking it up
It matters as a systems-biology peptide rather than a trendy product name.
Neurotensin is an endogenous neuropeptide involved in gut-brain signaling, pain, temperature, and dopamine-related pathways.
Neurotensin tends to stay in the conversation because it touches a familiar public theme: neuropeptide, gut-brain signaling, and dopamine context. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Strong biology relevance with limited straightforward product translation.
Human biology is established, though therapeutic translation remains narrower than the physiology.
Mechanistic support across neuropeptide physiology is substantial.
Why this page carries the current tier: Strong biology relevance with limited straightforward product translation.
The current seed trail for Neurotensin is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
Broad neuropeptide roles make simple intervention claims unreliable.
Neurotensin is tracked here as endogenous biology.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Neurotensin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Neurotensin is CID 25077406. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 25077406
- Formula
- C78H121N21O20
- Molecular weight
- 1672.9
- InChIKey
- PCJGZPGTCUMMOT-ISULXFBGSA-N
Matched synonyms include NEUROTENSIN, 39379-15-2, Neurotensin 1-13, XHB61LG5QS, DTXSID4041076, CHEBI:7542, RefChem:927681, (2S)-2-(((2S,3S)-2-(((2S)-2-(((2S)-1-((2S)-2-(((2S)-2-(((2S)-1-((2S)-6-amino-2-(((2S)-4-amino-2-(((2S)-4-carboxy-2-(((2S)-3-(4-hydroxyphenyl)-2-(((2S)-4-methyl-2-(((2S)-5-oxopyrrolidine-2-carbonyl)amino)pentanoyl)amino)propanoyl)amino)butanoyl)amino)-4-oxobutanoyl)amino)hexanoyl)pyrrolidine-2-carbonyl)amino)-5-(diaminomethylideneamino)pentanoyl)amino)-5-(diaminomethylideneamino)pentanoyl)pyrrolidine-2-carbonyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylpentanoyl)amino)-4-methylpentanoic acid.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Neurotensin returns 17 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Neurotensin returns 6341 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Anti-Stress Drops 2009
- Generic names
- ANTI-STRESS DROPS
- Routes
- ORAL
- Application numbers
- Not linked
Indications and usage. INDICATIONS For temporary relief of anxiousness, irritability, fatigue, restlessness, muscle tension, or occasional headache associated with stressful situations.*
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.